INVO Bioscience, Inc. (INVO)
After hours:
| Previous close | 1.5200 |
| Open | 1.3900 |
| Bid | 1.0500 x 200 |
| Ask | 1.6800 x 200 |
| Day's range | 1.3000 - 1.4700 |
| 52-week range | 0.5000 - 10.5000 |
| Volume | |
| Avg. volume | 3,822,170 |
| Market cap | 3.758M |
| Beta (5Y monthly) | 1.49 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.1300 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
INVO Reports Fourth Quarter and Full Year 2023 Financial Results
SARASOTA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics, and with the intravaginal culture ("IVC") procedure enabled by its INVOcell® medical device, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a business update.
GlobeNewswireNAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)
NAYA to accelerate Phase II clinical development and Early Patient Access after initial safety demonstrated in 28-patient clinical trialProgram developed by Florida Biotechnologies, Inc. & the University of Miami’s Bascom Palmer Eye InstituteNAYA continuing to implement acquisition roll-up of clinical and commercial assets in oncology, regenerative medicine, and fertilityNAYA expects to close its previously announced merger with INVO Bioscience (NASDAQ: INVO) in the first quarter of 2024 followi
- GlobeNewswire
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors
INVO (NASDAQ: INVO) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024Experienced, entrepreneurial leadership team to help structure merged public company and accelerate growth SARASOTA, Fla. and AVENTURA, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, a healthcare services company focused on expanding access to advanced fertility treatment worldwide, which has recently signed a definitive merger agreement with NAYA Biosciences (“NAYA”)
